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Abstract: Immunosuppression (IS) following solid organ transplantation is indicated to avoid rejection but puts a sig-
nificant burden on patients and healthcare systems due to life-long medication dependency and associated costs. Or-
gan-tolerance with low or no IS medication has been observed, and might be forecasted with the help of appropriate 
biomarkers. Individualized treatments raise the question whether benefits of individualization outweigh the costs of 
stratification. This article outlines the importance of early economic evaluation in the context of biomarker-guided IS 
and discusses challenges that an economic evaluation should address, using the BIO-DrIM project as a reference exam-
ple. We report on design aspects and health-economic study integration into several newly designed biomarker trials. In 
these studies, health-economic endpoints were defined to measure benefits of individualization and to compare them to 
the costs associated with stratification. Key economic outcomes to be collected are resource consumption and patient 
quality of life. Test accuracy of the biomarker-stratification is critical for the clinical success and the health-economic 
viability of an individualized reduced IS regime. However, IS regimes are not well standardized, rendering comparator 
choice difficult. The multi-national character of the trials adds further complexity that needs to be addressed. Develop-
ers of biomarker tests should stress the importance of integrating health-economic evaluations early into prod-
uct-development. 
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Introduction 
Immunosuppression Following Solid Organ Trans-
plantation 
olid organ transplantation is the treatment of 
choice for many indications involving organ 
failure and malfunction. To avoid rejection of 
the transplanted allografts it is necessary to apply 
immunosuppressive drugs, typically for the rest of a 
patient`s lifetime. Life-long immunosuppression (IS) 
puts a significant burden on patients due to potentially 
severe medication-related side-effects. At the same 
time, it puts a significant burden on health-care sys-
tems due to high medication costs and costly treat-
ments of side-effects.  
Typical current immunosuppressive therapies are 
not well standardized and consist of a combination of 
three to four immunosuppressant agents that are com-
bined based on a clinical assessment and on individual 
weighting of patient-specific risk-factors, including 
each patient`s ability to metabolize the various IS med-
ications. The patient-specific risk stems from two op-
posing features of IS medication; under-exposure to IS 
may lead to rejection episodes, organ damage, and/or 
graft-loss, while over-treatment involves an increased 
risk of opportunistic infections (especially EBV, CMV 
and BKV) and malignancies, as well as drug-specific 
complications including post-transplant diabetes mel-
litus, nephrotoxicity and hypertension[1]. In order to 
find the right balance according to dosing and IS com-
binations for each patient, therapeutic drug monitoring 
(TDM) is employed to control blood trough levels of 
several components of the IS medication[1].  
Experience from past clinical trials revealed that the 
risk for acute rejection episodes is highest during the 
first three months after transplantation[2]. Therefore, it 
has been argued that the IS regimen should be highest 
during this initial period, but should be tapered after-
wards to limit severe side effects. As a result, IS 
medication protocols were refined and can today be 
separated into an induction and a maintenance phase. 
No scientific consensus has been reached yet in which 
patients, at what time, and how fast the tapering of 
which component of IS medication should be con-
ducted[2–3]. This is particularly striking not only in 
light of the many undesirable side-effects that limit the 
overall effectiveness and the patient’s adherence to 
therapy, but importantly also in light of the high cost 
of IS-induction therapy with Basiliximab or Alemtu-
zumab. For example, the 2-year costs of four different 
immunosuppressive strategies, either based on Siroli-
mus, Cyclosporine, Everolimus or Tacrolimus, have 
been shown to vary between 26,732 EUR and 49,978 
EUR[4]. 
Organ-tolerance in patients that are effectively on 
low IS medication or no IS medication at all, has been 
observed in many patients with various transplanted 
types of allografts[5–7]. Unfortunately, organ tolerance 
without IS medication cannot be reliably anticipated 
to date. Based on these observations, the clinician`s 
desire to find safe and tolerable strategies to minimize 
IS following SOT becomes evident. 
A clinically feasible solution could be a routine as-
sessment of suitable biomarkers to detect patients who 
will be tolerant to the allograft with low IS medication 
or no IS medication at all. Such biomarkers have been 
discovered, but their routine assessment and the re-
lated precision with regard to correct patient stratifica-
tion and the corresponding health-economic profiles 
of such strategies have not been studied to-date in 
prospective RCTs.  
Need for Economic Evaluation of Biomarker-guided 
Reduction of Immunosuppression 
Several useful biomarkers were identified in the field 
of solid organ transplantation throughout the last 
years[8,9]. They can be grouped into pre- and post- 
transplant markers indicating either a high risk for 
rejection or tolerance of patients towards their trans-
plant. In the case of renal transplantation they might 
even be used to personalize immunosuppression re-
gimes and dosages and to establish success of toler-
ance-inducing or immunosuppression minimization 
protocols. The combination of several markers could 
even further improve the quality of such a test, com-
pared to a single biomarker[6]. 
Once safe mechanisms for the minimization of IS 
have been identified and established, there is a strong 
belief that these strategies would inevitably be cost- 
effective and even lead to overall monetary savings 
for respective healthcare systems[3]. However, this is 
not necessarily the case, especially when pre-tran-
splant stratification is expensive and/or only a small 
cohort can profit from reduced IS medication. Even if 
the costs of a routine pre-transplant biomarker test 
were small, the effects on a patient population in terms 
of costs for treatments of IS side-effects, rejection 
episodes and subsequent hospital admissions and out-
patient visits can be substantial, justifying the need for 
quantitative health-economic evaluation[10]. Indeed, pre-
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liminary data coming from non-randomized biomarker- 
driven multi-center pilot studies[11] have shown the 
feasibility of such studies enabling the identification 
of such group of transplant patients that may benefit 
of low immunosuppression with comparable efficacy 
outcomes as compared to patients receiving high bur-
den immunosuppression. 
Many health-economic evaluations have been con-
ducted in the field of IS medication[4,12–14], but to our 
knowledge there is no health-economic evaluation 
published to-date about the cost-effectiveness and/or 
cost-utility of a biomarker-guided (individualized) 
reduced IS medication plan following solid organ 
transplantation.  
Moreover, the standards for health-economic eva-
luations are currently not well defined in the field of 
personalized treatment strategies, as already stated by 
Hall et al.[15]. A fact that may pose a threat for devel-
opers due to delayed approval and uptake of 
care-improving and individualized treatments as well 
as for patients` health in consequence. The BIO-DrIM 
consortium in general and this paper in particular seek 
to contribute to identifying challenges specific to the 
health-economic evaluation of personalized treatment 
strategies and present suggestions on how those chal-
lenges could be addressed.  
The BIO-DrIM consortium is made up of sixteen 
partners, including clinical institutions, universities, 
research-performing SMEs, and big-pharma companies. 
Seven countries are represented: Germany, France, Italy, 
the United Kingdom, the Netherlands, Czech Republic 
and Spain. The participating groups have been chosen 
for their scientific excellence, technical expertise, and 
experience in translational research. The BIO-DrIM 
project includes five investigator-driven biomarker 
clinical trials in the field of kidney and liver trans-
plantation designed by the consortium with more than 
thousand patients in six EU member states. An impor-
tant challenge, although not specific for biomarker- 
evaluation, arises from the multi-national character of 
the clinical trials: since trial data will come from pa-
tients in various healthcare systems with varying re-
imbursement regulations, a normalization strategy 
will need to be applied to our analyses.  
This paper further illustrates the importance of 
health-economic considerations in evaluating the ben-
efits of future biomarker-driven immunosuppression 
(BIO-DrIM). Special interest was given to the ques-
tion, whether or not additional benefits related to a 
pre- transplantation stratification strategy — e.g. due 
to increased quality of life (QoL) or less side-effects 
and post-transplantation costs — outweigh the costs of 
prospective stratification.   
Materials and Methods 
Early Health-economic Evaluation 
Health-economic evaluations become increasingly im-
portant in the field of product development and health 
technology assessment (HTA) as national healthcare 
budgets seek to allocate financial resources more and 
more efficiently. Health-economic evaluations aim to 
identify treatment-related health outcomes and costs 
and put both in relation to each other in order to in-
form policy decisions as well as marketing approval, 
reimbursement, and other decisions (e.g. internal in-
vestment decisions). It is recommended to integrate 
health-economic considerations into product devel-
opment decisions at early stages in order to make de-
velopers familiar with health-economic benchmarks 
that need to be met and thereby to continuously reduce 
the inherent uncertainty throughout the development 
phase[16]. Another advantage of early integration of 
health-economics is the ability to provide health- 
economic data for authorities at early stages and mak-
ing the authorities familiar with the intervention under 
consideration. Engaging in early dialogue with payers 
and regulators proved to be useful from a developer`s 
perspective[17,18]. 
Health-economic Decision Problem in the Context 
of Biomarker-guided IS  
The resulting health-economic decision problem of the 
BIO-DrIM trials can be summarized as outlined in 
Figure 1. Traditional IS regimen (referred to as “High 
IS” in our context) based on a clinical assessment, and 
individual weighting of patient-specific risk-factors 
represent the standard of care (SoC) and are referred 
to as comparator. Health-economic outcomes for this 
strategy will be collected and compared with the out-
comes of the innovative biomarker-guided strategy 
that intends to taper IS for eligible (negatively tested) 
patients and let other patients (positively tested) re-
main on standard IS medication (High IS). The se-
lected health-economic outcomes have been defined in 
close collaboration with clinical scientists and are de-
scribed in the next section. 
Health-economic Endpoints 
The assessment of health-outcomes is a complex subject 
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Figure 1. Health-economic decision problem of biomarker-guided IS 
following SOT. Health-economic outcome evaluation primarily based 
on costs and QALYs should compare the results of the biomarker- 
guided strategy with those of standard of care for the same patient 
cohort. Standard of care represents a high dosing of immunosuppres-
sive medication, while patients receiving the biomarker-guided immu-
nosuppression, will be assessed prior to transplantation and stratified to 
high (in case of a high risk for rejection) and low IS (in case of a low 
risk for rejection) accordingly. 
 
as appealingly outlined by Sculpher and Claxton[19]: 
“Technologies in one disease area (e.g. diabetes) often 
have impacts on outcomes in other areas (e.g. cardio-
vascular, wound management, ophthalmology, etc.), 
each with specific measures of outcome. Therefore, 
technologies are likely to offer a complex prospect of 
effects on very many dimensions and measures”. The 
major challenge is to make health outcomes in various 
dimensions comparable to each other or even across 
indications. This can be achieved through calculation 
of Quality-Adjusted Life Years (QALYs).  
QALYs take into account both, subjective quality 
and objective quantity of remaining life years. The 
remaining QALYs of a patient equal the arithmetic 
product of life expectancy and a measure of the qual-
ity of the remaining life-years. According to the sub-
jective quality of a life-year, a QALY places a respec-
tive weight on time in different health states. A year in 
perfect health is worth 1 and a year of less than perfect 
health is worth less than 1, with death being consid-
ered to equal 0. In clinical practice, QALYs are rou-
tinely assessed with the help of standardized ques-
tionnaires, like the SF-36v2, EQ-5D and others.  
Figure 2 shows an exemplary QALY-comparison of 
two hypothetical treatments, and highlights the QALY 
gain of an innovative treatment approach. Please refer 
to Cohen et al.[20] for a detailed description of  
 
 
Figure 2. Exemplary QALY gain. 
 
the preference-based QALY concept. The primary 
health-economic endpoints in all BIO-DrIM trials are 
QALYs, costs, and costs per QALY per patient at the 
end of follow-up. These outcome measures are needed 
for conducting cost-utility analyses. Furthermore, from 
a health-economic perspective several additional 
clinical endpoints are important in order to analyze the 
cost-effectiveness of biomarker guided IS following 
SOT. Therefore, patient survival (mortality), organ sur-
vival (graft-loss), and biopsy-proven acute rejection 
episodes (BPAR) are assessed in this study and sub-
sequently used in the cost-effectiveness analyses. 
Quality of Life — Instruments and Timing of the 
Assessment 
Quality of life (QoL) will be assessed using the gen-
eric SF-36v2 and the EQ5D-5L questionnaire, with the 
latter being used for QALY conversion. The disease- 
specific Kidney-Transplant-Questionnaire-25 (KTQ-25) 
will be administered in the case of renal transplanta-
tion, and the NIDDK questionnaire in case of liver 
transplantation in order to capture other disease-rel-
ated aspects of QoL that cannot be detected by the 
generic questionnaires, or for which the QALY meas-
ure is not sensitive enough. These questionnaires are 
summarised in Table 1. 
The generic EQ5D-5L questionnaire is a widely 
accepted QoL instrument, and has been recommended 
by various healthcare payers[17]. It will be adminis-
tered at baseline (randomization), at Months 1, 3, 6, 
12, 18, and 24. Results will be recorded in electronic 
case report forms (eCRF) and Index-values will be 
calculated from the answers for each administration. 
Subsequently, QALY-weights will be obtained using 
official crosswalk value sets for Spain, UK, France,  
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Table 1. Quality of life instruments in BIO-DrIM trials 
Quality of Life Instruments to be applied in BIO-DrIM Trials 
Questionnaire Type Dimensions 
EQ5D-5L Generic Mobility, Self-Care, Usual Activities, Pain / Discomfort, Anxiety / Depression 
SF-36v2 Generic Vitality, Physical Functioning, Bodily Pain, General Health Perceptions, Physical Role Functioning, Emotional Role Functioning, Social Role, Functioning, Mental health 
KTQ-25 Disease-specific Symptoms related to kidney transplantation and subsequent Immunosuppression 
NIDDK Disease-specific General, Work, Health, Symptoms, Quality of Life 
 
Czech Republic, Netherlands, and Germany. The mean 
and median values of accumulated QALYs will be 
determined for each IS strategy and compared against 
each other. 
The generic SF-36v2 questionnaire is also a widely 
accepted QoL instrument, and has likewise been rec-
ommended by various healthcare payers[17]. It will be 
administered at the same time-points as the EQ5D-5L 
and the other QoL questionnaires. Answers will be 
recorded in an eCRF, evaluated and further transfor-
med according to the official SF-36v2 manual. Scor-
ing of the questionnaire outcomes will be conducted 
using QualityMetric’s Scoring Software v4.5. Scores 
of each subscale as well as total scores will be com-
pared between treatment arms and between complete 
treatment-strategies where possible. Specific focus 
will be given to an exploratory comparison of mean 
scores of subscales between treatment arms to detect 
differences in specific aspects of QoL that are not an-
ticipated yet. Furthermore, a mapping of SF-36 results 
to QALY weights will be performed as cross-check, to 
ensure a high quality of results with respect to QALYs 
that will further be used in cost-utility analyses and 
health-economic modelling[21].  
In trials recruiting renal transplant recipients, the 
disease-specific QoL questionnaire, KTQ-25 by An-
dreas Laupacis[22], will be administered at the same 
time points as the other QoL instruments. The KTQ- 
25 has been validated for various countries, including 
Spain, the US and others[23–25]. It focuses on symp-
toms related to the transplantation and immunosup-
pression context. It will be used to compare the de-
velopment of various symptoms between treatment 
arms. This analysis reflects a rather exploratory inves-
tigative approach.  
In line with most recent health-economic guide-
lines[26–28], the timing of the QoL assessments has 
been set according to expected changes in QoL be-
tween treatment arms on the one hand and according 
to practical considerations (assessment at regular 
study visits) on the other hand. Most frequent adverse 
events as well as problems related to immunosuppres-
sion are likely to occur early during follow-up[2,29]. 
Therefore we decided to evaluate QoL more often 
during the first year with a gradual decrease in as-
sessment frequency (at randomization, M1, M3, M6, 
M12) and less frequently during the second year of 
follow-up (M18 and M24). In addition to that, we will 
assess QoL at baseline (randomization) in order to 
adjust for imbalances at the outset of the trial. 
Cost-assessment — Instruments and Timing  
The intended cost-assessments within the BIO-DrIM 
trials will follow the general steps of identification, 
measurement (counting), valuation, and discounting of 
resources. The cost-assessment can be separated into 
two major blocks: 
(i) Micro-costing procedure to determine appropri-
ate costs for the biomarker-stratification procedure in 
specialized laboratories 
(ii) Assessment of patient-specific resource con-
sumption, employment status and medical leave peri-
ods by using situation-dependent and study-specific 
questionnaires for patients and study personnel at 
regular study visits (M3, M6, M12, M18, M24) and in 
cases of repeated hospitalizations. 
The assessed values for resource consumption will 
be valued with appropriate prices and discounted / inf-
lated to a present value according to health-economic 
guidelines[26–28]. The results will further be used in sub-
sequent cost-effectiveness and cost-utility analyses. 
Micro-costing to Determine Appropriate Costs for 
Biomarker-stratification Procedure 
Micro-costing is a method proved to be useful for de-
termining detailed cost items of healthcare interven-
tions[30]. It involves the identification, measurement, 
valuation and discounting of resource consumption 
items. An example of conducting micro-costing pro-
cedures in a laboratory environment is provided by 
Abou-El-Enein et al.[31].  
Simon Anton Weber, Malte Pietzsch, Oriol Bestard, et al. 
 
 Advances in Precision Medicine, vol 1, issue 1, 2016 71 
Xu et al. report that there is currently a lack of 
standardization in existing health-economic guidelines 
that could improve “quality and transparency of future 
studies and enhance comparability and interpretation 
of findings[30]. However, an appropriate strategy to 
determine the costs associated with the biomarker- 
stratification procedures is provided by Fitzgerald et 
al.[32]. The outlined micro-costing strategy focuses on 
the fact that variability in results is expected for vari-
ous patients[32]. Therefore, a sub-study was initiated 
with a subset of the trial participants to conduct the 
micro-costing procedure and detect potential differ-
ences between patients as well as between treatment 
arms. 
In addition to the inter-patient variability, we also 
expect inter-lab differences in total biomarker-costs 
between six European study centers. These differences 
can occur due to varying regulations on best-practice 
standards, and/or differences in sample processing in 
the labs of the various countries and by other factors 
related to national variations in workflow, salary, 
price-levels, inflation rates, etc.  
Since biomarker assessment could be conducted cen-
trally or locally, depending on the specific BIO-DrIM 
trial, different micro-costing strategies have been 
proposed to account for the variabilities as described 
earlier. Whenever a central assessment of biomarkers 
is planned in a trial (e.g. by a central pathologist to 
ensure rater-consistency), it is impossible to conduct a 
sub-study with several labs in several countries, to 
account for the international variability in results. In 
order to detect potential inter-patient variability, we 
will perform structured interviews with the central 
laboratory personnel during the course of the mi-
cro-costing procedure. Whenever a local assessment 
of the biomarker test is intended, additional inter-lab 
comparisons will be performed with respect to the 
micro-costing procedure to identify systematic inter-
national variability in results. 
Patient-level Cost-assessment of the Treatment Arms 
Patient-level cost-assessment tries to capture as much 
relevant information as possible requiring a justifiable 
effort for study personnel and focuses on healthcare 
utilization during the follow-up in the treatment 
arms[33]. The higher the effort for study personnel and 
patients to assess specific data elements the higher are 
the chances for systematically missing values[34]. The-
refore, costs will be assessed using specifically de-
signed health-economic questionnaires. The items of 
the questionnaires have been identified with the help 
of the principal investigators (PI) and other trial staff 
in accordance with health-economic guidelines[26, 35–37]. 
They comprise so-called “big-ticket” items (e.g. di-
alysis, re-transplantation, costly cancer treatments as a 
consequence of over-IS, etc.), items of resource con-
sumption that are likely to differ between treatment 
arms (e.g. frequencies of BPAR, severe infections, 
malignancies and the respective treatments, frequen-
cies of serious adverse effects of IS, etc.), information 
about outpatient healthcare utilization, dependency on 
care-giving, employment status and medical-leave 
periods (costs for IS regimen as well as concomitant 
medications will be tracked separately and incurred in 
the analyses). A summary of the most important cost 
items to be captured is provided in Table 2. 
 
Table 2. Cost items in BIO-DrIM trials 
Cost items to be recorded within BIO-DrIM Trials include but 
are not limited to: 
 Inpatient LOS 
 Time spent in each hospital ward (e.g. ICU, surgery, nephrology etc.) 
 Major diagnostic assessments (e.g. CT, MRI, etc.) 
 Major therapeutic procedures (e.g. Revision surgery, other sur-
gery, chemo-therapy, etc.) 
 Treatment of complications (e.g. rejection episodes) 
 Post-transplantation diseases (e.g. stroke, myocard infarction, etc.) 
 Re-transplantation 
 Dialysis 
 Outpatient visits incl. reason for visit and applied services 
 Employment status  
 Medical leave periods 
 Dependency on care-giving 
 
Up to three different versions of the questionnaire 
have been designed to suit various situations in the 
study context. They are: 
 Details of initial hospitalization, including trans-
plantation procedure (to be completed by trial 
staff using information from patients’ medical 
records at initial discharge) 
 Details of repeated hospitalization (to be com-
pleted by trial staff using information from pa-
tients’ medical records, and from interview with 
the patient, at repeated discharge) 
 Details of regular study visits (to be completed 
by trial staff using information from patients’ 
medical records, and from interview with the pa-
tient, at regular study visits) 
Details of initial hospitalization cover all relevant 
inpatient major diagnostic assessments, procedures 
and respective justifications for those during the initial 
hospitalization period, including the transplantation 
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procedure. This assessment is also needed to adjust 
total patient-specific costs for relevant baseline dis-
parities which are not attributable to the immunosup-
pression context. The questionnaire on details of re-
peated hospitalizations was designed to cover inpa-
tient resource consumption in case of major complica-
tions, disease-related or not, requiring a repeated stay 
in the hospital. 
The third version of the health-economic question-
naire will be applied in the case of regular study visits. 
It covers dialysis and post-transplantation diseases, em-
ployment status and medical leave and details about 
potential outpatient healthcare utilization. The timing 
of the cost-assessment was defined according to prac-
tical trial-considerations and major health-economic 
needs. The assessment of information about resource 
consumption at the initial discharge of each patient, 
follows the health-economic need to adjust for base-
line disparities, that are not attributable to the IS con-
text. In case of a repeated hospitalization, it is as-
sumed that a major complication occurred. This com-
plication potentially represents another “big-ticket” 
item and respective information should be recorded. 
Last but not least, non-troublesome patients should be 
assessed with regards to their healthcare utilization at 
regular study visits at M6, M12, M18, and M24. 
Results / Discussion  
Health-economic Challenges Stemming from IS 
Context 
The BIO-DrIM consortium faces a special situation in 
the field of health-economics, because the IS strate-
gies under consideration are intended to evaluate re-
duced medication plans. Typically, health-economists 
are dealing with the evaluation of innovative treat-
ments, add-on treatments, medical devices and other 
healthcare interventions that are associated with in-
creased expenditures and improved health outcomes at 
the same time. The resulting decision problem can be 
summarized as follows: “Is a payer willing to spend 
the additional amount of X monetary units for an addi-
tional unit of health (e.g. QALY)?” whereby the nec-
essary monetary amount of X is determined by quan-
titative health-economic assessments. Taking these 
results into consideration, a fair decision-maker would 
apply an objective decision rule in the form of an up-
per boundary for accepting costly innovative treat-
ments. For example, the maximum cost-effectiveness 
threshold in the UK is £30,000/QALY gained[38], mea-
ning that the decision maker would accept treatments 
associated with additional maximum costs of £30,000 
per QALY gained by the intervention in comparison to 
the standard of care. 
In the context of evaluating biomarker-guided re-
duced IS medication, chances of ending up in a situa-
tion associated with less total costs, but improved 
health are clearly present. However, the following 
rationale needs to be adequately addressed in the con-
text of reduced IS medication in order to produce re-
liable health-economic results. When reduction of IS 
is indicated by a respective pre-transplant biomarker 
result, it can only be performed in a controlled fashion 
in order to assure patient safety. Due to individual pa-
tient-specific metabolism of IS medication, therapeu-
tic drug monitoring (TDM) needs to be performed to 
reach previously defined IS-concentration target-lev-
els in the patient’s blood. The assessments of IS med-
ication concentration in blood levels (TDM) is rou-
tinely performed during outpatient visits and are less 
frequently necessary for patients on a standard “High 
IS” regime, once they reached a stable trough target- 
level. This fact potentially increases expenditures for 
those patients on a reduced IS regime, because they 
will probably need more frequent blood-level checks 
to reach continuously decreasing IS-concentration 
target-levels. Although several effects have been iden-
tified that might lead to reduced expenditures for pa-
tients receiving reduced IS, the outlined argumenta-
tion might drive cost results in the opposite direction 
and it is not clear to-date whether or not reduced IS 
regimen are really associated with reduced expendi-
tures per se.  
We reviewed clinical guidelines[39,40] in the field of 
IS following renal transplantation and created a plan 
for expected outpatient visits for blood level concen-
tration measurements. According to this plan, we ex-
pect four additional outpatient visits for blood level 
concentration measurements for patients with reduced 
IS medication. Table 3 illustrates the timely assess-
ments of CNI blood concentration levels.  
Another important aspect in the context of health- 
economic evaluation of reduced IS regimes, is the 
appropriate comparator choice. As outlined above, he-
alth-economic evaluations compare specific outcomes 
between competing treatment options. IS regimes are 
only fairly standardized as already discussed. This 
renders the correct comparator choice difficult. Since 
the IS regimes under consideration usually vary even 
between study-centers of a single country, a unique  
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Table 3. Expected schedule for CNI blood level trough concentration measurements (suggested minimum amounts according to ref-
erenced guidelines & protocols) 
 
* suggested clinic frequency by Baker et al. 2011: "We suggest that uncomplicated patients, as a general rule, may be reviewed progressively less 
frequently in clinic: 2–3 times weekly for the first month after transplantation; 1–2 times weekly for months 2–3; every 1–2 weeks for months 4–6; 
every 4–6 weeks for months 6–12; 3–6 monthly thereafter." 
** suggested blood level measurement frequency by Kasiske et al. 2010: "We recommend measuring CNI blood levels (1B), and suggest measur-
ing at least: every other day during the immediate post-operative period until target levels are reached (2C); whenever there is a change in medication 
or patient status that may affect blood levels (2C); whenever there is a decline in kidney function that may indicate nephrotoxicity or rejection." 
*** expected TAC steady state according to LeGatt: "Time to steady state: Tacrolimus: 2–6 days (at least four doses)" 
 
standard high IS regime has been defined for all 
BIO-DrIM trials in consent among the participating 
study centers. Several options of induction and main-
tenance IS strategies have been intensely discussed 
among clinicians and a common standard of care was 
defined. 
Health-economic Challenges Stemming from Bio-
marker-Assessment Context 
Test accuracy is a key parameter in determining 
cost-effectiveness and cost-utility of biomarker-guided 
IS reduction. Assuming a patient has been tested false- 
negative, the IS medication would be reduced alth-
ough the patient belongs to the high risk-group for 
developing rejection episodes. This would put the pa-
tient at an inappropriate risk, with potentially severe 
consequences for the patient`s health. Also from a 
health-economic perspective, such a situation would 
result in higher costs than necessary and poorer health 
for the patient assuming the patient rejects the al-
lograft. Additional costs stemming from the treatment 
of rejection episodes induced by the inappropriately 
reduced IS will need to be accounted for in this case. 
Fewer problems are associated with patients being 
tested false-positive; these patients would receive 
standard high IS medication although they would be 
eligible for a reduced medication plan. Clinical results 
might be less optimal than under a reduced medication 
regime, due to higher rates of side-effects. However, 
this treatment currently represents the standard of care 
and can therefore be regarded as appropriate. As out-
lined above, health-economic results of individualized 
treatment strategies are not only influenced by test  
accuracy of the stratification procedure but also by the 
size of the resulting patient cohorts. Assuming a test is 
available that can separate patients into two groups, 
one for which the status-quo treatment is optimal and 
another for which a refined treatment is optimal. The 
overall health-economic profile of an individualized 
strategy (in comparison to status-quo treatment for all) 
deteriorates as the size of the beneficial cohort shrinks. 
This becomes obvious in consideration of the amount 
of patients with better health outcomes who could 
compensate the additional costs of stratification. 
When evaluating biomarkers for routine clinical 
applications from a health-economic perspective, it is 
necessary to assign a certain price to the respective 
assessment. In order to find an appropriate price, pre-
cise estimates about the costs of performing the test 
need to be considered. As stated above, micro-costing 
offers an appropriate method for the assessment of 
costs that are associated with the biomarker assess-
ment. Depending on who will perform the test and 
where this is performed in a clinical trial setting, com-
plementing approaches can be employed to account 
for inter-patient, inter-lab, and inter-national variabil-
ity of micro-costing results. Since the relevant bio-
markers will be assessed centrally in BIO-DrIM trials, 
we will run a micro-costing approach in the central 
German study lab. In addition to that, we will obtain 
prices of input factors from as many participating 
countries as possible to get an impression about how 
the actual costs of the biomarker-assessment will vary 
between the affected countries. 
Challenges Related to Early Health-economic 
Evaluation  
Health-economic evaluation is recommended to be 
integrated into the development cycle of innovative 
treatments and devices already at early stages[16]. This 
month post transplantation
week post transplantation W6 W7 W8 W9 W10 W11 W12
day post transplantation 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 42
suggested clinic frequency* x x x x x x x x x x x x x x x x x x x x x x
blod level checks HIGH** x x x x
blood level checks REDUCED*** x x x x x x x x
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can be done already as soon as the initial innovation 
idea has been formulated. By using comparably rough 
estimates and methods, initial rough estimates about 
costs and health outcomes can be obtained at very 
early stages of development. The performed health- 
economic evaluations can then be subsequently re-
fined throughout the development process with regard 
to the employed methods and estimates as input fac-
tors to the analyses. In doing so, health-economic re-
sults are continuously refined, and more reliable re-
sults are obtained by reducing the inherent uncertainty 
related to the results. It is believed that this strategic 
approach will reduce uncertainty associated with ap-
proval and/or reimbursement decisions. 
With regard to the BIO-DrIM trials, this approach 
was chosen as it reflects most recent finding of health- 
economic guidelines. Although, phase II trials are also 
part of the consortium, we intend to collect as much 
health-economic evidence as possible after accounting 
for the trade-off between effort to be made to obtain 
certain data and accuracy of results that can be ex-
pected. 
Health-economic Challenges Stemming from 
Multi-national Trial Context 
Multi-national clinical trials are increasingly emplo-
yed in various indications. Especially for health-eco-
nomic evaluations, the multi-national character of a 
trial raises additional issues. One of them is the app-
ropriate choice of perspective for the analysis[41]. 
Health-economic evaluations are designed to inform 
specific stakeholders of the health-care system: reim-
bursement and approval authorities, hospitals, devel-
opers / scientists, patients and several more. Depend-
ing on the stakeholder who shall be addressed with an 
evaluation, various types of costs should be incurred 
in the analysis (see Table 4). Furthermore, various 
timeframes for an analysis will be relevant depending 
on the stakeholder to be addressed: a hospital might be 
interested in yearly outcomes while an insurance 
company is interested in outcomes over a life-time 
horizon. The longer the chosen time-frame and the 
broader the perspective of an analysis, the more spe-
cific the data on costs and health outcomes need to be 
assessed.  
For the BIO-DrIM trials the follow-up period was 
determined based on clinical considerations focusing 
on proving improved long-term graft survival without 
compromising short-term graft survival. The cost-per-
spective was discussed and defined in close collabora-
tion with clinical scientists and comprises of all direct 
medical and direct non-medical costs as well as of 
other big-ticket items, e.g., periods of medical-leave 
and potential dependency on care giving during the 
follow-up. The choice of cost items was based on the 
idea to perform the health-economic analyses from the 
perspective of the German Statutory Health-Insurance 
(SHI), justified by the fact that the biggest share of 
patients will be recruited from three German study 
centres. Additionally, Germany is often being referred 
to as a reference market from a developer`s perspec-
tive. All economic results will therefore be calculated 
in EUR and discounted to a present value according to 
health-economic guidelines[26].  
Limitations 
BIO-oDrIM will be the first initiative launching bio-
marker-based randomized clinical trials in almost one 
thousand patients with the unique intention to ulti-
mately reduce IS medication in suitable patients. How-
ever, due to the various challenges that need to be con-
sidered from a health-economic perspective and are 
outlined above, several limitations of the presented st-
udy framework need to be kept in mind and addressed 
during the analysis- and interpretation-phase. 
Partly unreliable health-economic results might stem 
 
Table 4. Possible perspectives of economic evaluations and their related costs (adapted from IQWiG[36]) 

































e Direct medical costs Diagnostics, procedures, drugs, wages for physi-cians and nurses, etc. yes 




Wage compensations, transfer payments to other 
social insurance schemes, care giver time, etc. sometimes 
 Indirect costs Productivity losses, reduced tax payments due to incapacity for work and reduced consumption, etc. 
no 
 
* typical reimbursement status referring to standard health insurance contracts in affected countries 
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from the multi-national character of the trials: Differ-
ent best-practice standards have developed independ-
ently in various countries, especially with respect to 
the treatment of side-effects of IS medication includ-
ing BPAR. Since we do not expect perfect biom-
arker-stratification as well as imperfect IS medication, 
a small amount of patients to reject their organ no 
matter in which treatment arms. We have to expect 
that they will be treated differently according to the 
best-practice in the respective study center, impeding 
the standardized treatment patterns in the trials and 
therefore rendering the analysis difficult.  
Another problem refers to the cost-assessment of 
the biomarker stratification process. As we are dealing 
with central labs throughout the BIO-DrIM trials, we 
cannot perform inter-lab comparisons. These would 
have helped in the detection of international variabil-
ity in biomarker-provision costs. They can occur due 
to different working procedures in the laboratories 
under investigation, different wage-levels, and varying 
costs for other input factors. Therefore we will assess 
the biomarker-provision prices for Germany and col-
lect those input factors that might be available in other 
countries for different costs to get a notion of potential 
variability. 
Conclusion 
Health-economic profiles of biomarker-guided redu-
ced IS regimen have not been studied to date in con-
nection to prospective randomized controlled clinical 
trials. It is not clear whether or not individualized re-
duced IS regimen are associated with less expendi-
tures, due to the expected effects outlined above, jus-
tifying the need for comprehensive health-economic 
analyses as personalized IS treatment options follow-
ing SOT become available in clinical routine practice. 
Several challenges from a health-economic perspec-
tive have been identified during the course of defining 
the trials. We outlined how they have been addressed 
within the BIO-DrIM Trials. 
When a reduced immunosuppressive regime is 
evaluated, it is important to track all associated ser-
vices to conduct a safe IS weaning protocol. As TDM 
is extremely relevant in this case, outpatient visits, 
especially those with TDM focus, should be tracked in 
clinical biomarker trials. Furthermore, in the context 
of IS following solid organ transplantation, compara-
tor arms should be clearly defined as standard practice 
with respect to IS medication is substantially variable 
between European countries, and even single hospitals. 
The definition of a common comparator should be 
consented with all responsible physicians of a trial. 
Last but not least, test accuracy is not only central for 
the clinical applicability but also from a health-econo-
mic perspective. 
Another interesting aspect from the health-econo-
mic perspective has been appealingly outlined by Her-
nandez-Fuentes and Lechler (2010)[6]: Personalized IS 
regimen that are associated with less toxicity and 
side-effects would not only cut expenditures for drugs 
but also increase the lifetime of the transplanted organ 
and thereby increasing the availability of organs in the 
general population[3]. Health-economic analyses quan-
tifying this effect from a societal perspective should 
be conducted in the future to investigate the value to 
society stemming from an increased availability of 
donor organs. 
In this paper, we exclusively discussed the effects 
of pre-transplant biomarkers able to detect patient that 
are likely to be tolerant to the allograft with low levels 
 
Table 5. List of abbreviations 
Abbreviation Definition 
BIO-DrIM Biomarker-Driven personalized Immunosuppression 
BKV Human Polyomavirus 
BPAR  Biopsy-proven acute rejection  
CMV Cytomegalovirus 
CNI Calcineurin Inhibitor 
CT Computed Tomography (scan) 
EBV Epstein-Barr-Virus 
eCRF electronic Case Report Form 
HTA Health Technology Assessment 
ICU Intensive Care Unit 
IS Immunosuppression 
LoS Length of Stay 
M1, M2, … Month 1 after inclusion, month 2 after inclusion, … 
MRI Magnetic Resonance Imaging 
PI Principal Investigator 
QALY Quality Adjusted Life Year 
QoL Quality of Life 
RCT Randomized Controlled Trial 
SHI Statutory Health-Insurance 
SoC Standard of Care 
SOT Solid Organ Transplantation 
TDM Therapeutic Drug Monitoring 
W1, W2, … Week 1 after inclusion, week 2 after inclusion, … 
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of IS medication. However, post-transplant biomar-
kers are also available and may be used, e.g. to detect 
subclinical rejection episodes. In case a rejection is 
detected, counter-actions before irreversible organ 
damage has occurred can be taken and thereby en-
hance patient- and organ-survival. Furthermore, ava-
ilable and validated post-transplant biomarkers to de-
tect sub-clinical rejections would also ease the adop-
tion of IS weaning protocols and enhance the ethical 
acceptance of those strategies[6]. Health-economic 
profiles of such strategies have neither been studied to 
date, justifying the need for respective evaluations. 
Table 5 shows a list of abbreviations used. 
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